Stryker Co. (NYSE:SYK)‘s stock had its “buy” rating reaffirmed by equities research analysts at Deutsche Bank in a research report issued on Wednesday, Marketbeat reports.

Stryker (NYSE:SYK) traded up 2.69% on Wednesday, hitting $98.60. 6,548,427 shares of the stock traded hands. Stryker has a 52 week low of $86.68 and a 52 week high of $105.34. The stock has a 50 day moving average of $91.99 and a 200 day moving average of $96.69. The firm has a market capitalization of $37.03 billion and a PE ratio of 32.13.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 26th. The medical technology company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.01. During the same quarter in the prior year, the business earned $1.44 earnings per share. The company earned $2.70 billion during the quarter, compared to the consensus estimate of $2.71 billion. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. Equities research analysts anticipate that Stryker will post $5.11 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 31st will be issued a dividend of $0.38 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.27. This represents a $1.52 dividend on an annualized basis and a dividend yield of 1.58%. The ex-dividend date is Tuesday, December 29th.

In other Stryker news, Director Ronda E. Stryker sold 12,000 shares of the company’s stock in a transaction on Monday, January 25th. The stock was sold at an average price of $93.80, for a total value of $1,125,600.00. Following the completion of the sale, the director now directly owns 192,194 shares in the company, valued at approximately $18,027,797.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Katherine Ann Owen sold 12,144 shares of the company’s stock in a transaction on Thursday, December 31st. The shares were sold at an average price of $93.45, for a total value of $1,134,856.80. Following the completion of the sale, the vice president now owns 13,593 shares of the company’s stock, valued at $1,270,265.85. The disclosure for this sale can be found here.

A number of other analysts also recently issued reports on SYK. Zacks Investment Research upgraded Stryker from a “hold” rating to a “buy” rating and set a $103.00 price target for the company in a research report on Tuesday, September 29th. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research report on Friday, October 23rd. Canaccord Genuity reiterated a “buy” rating and set a $112.00 target price on shares of Stryker in a research report on Friday, October 23rd. Leerink Swann decreased their target price on Stryker from $110.00 to $109.00 and set an “outperform” rating for the company in a research report on Friday, October 23rd. Finally, Robert W. Baird lifted their target price on Stryker from $108.00 to $111.00 and gave the stock an “outperform” rating in a research report on Friday, October 23rd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $106.63.

A number of hedge funds recently modified their holdings of the stock. Terra Nova Asset Management boosted its stake in shares of Stryker by 2.1% in the third quarter. Terra Nova Asset Management now owns 32,776 shares of the medical technology company’s stock valued at $3,084,000 after buying an additional 676 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft bought a new stake in shares of Stryker during the third quarter valued at about $15,594,000. Gerstein Fisher boosted its stake in shares of Stryker by 10.3% in the third quarter. Gerstein Fisher now owns 5,472 shares of the medical technology company’s stock valued at $515,000 after buying an additional 513 shares during the last quarter. KBC Group boosted its stake in shares of Stryker by 5.2% in the third quarter. KBC Group now owns 37,516 shares of the medical technology company’s stock valued at $3,530,000 after buying an additional 1,871 shares during the last quarter. Finally, TrimTabs Asset Management bought a new stake in shares of Stryker during the third quarter valued at about $2,097,000.

Stryker Corporation is a medical technology company. The Company offers a range of products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes.

12 Month Chart for NYSE:SYK

Receive News & Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related companies with MarketBeat.com's FREE daily email newsletter.